SFN Phenotyping Questionnaire By introducing a new SFN phenotyping questionnaire (SFNPQ), we distinguished patient-reported pain in the skin, muscles and joints, see Appendix 1 for full questionnaire. The newly developed SFNPQ consisted of three different questions: 1. Do you feel pain intermittently or continuously? Intermittently Continuously 2. Please identify the anatomical level of pain: Pain in skin Pain in muscles Pain in joints Fill in: pain in … 3. Please mark the anatomical location of pain in the figure below, see Figure 1. Mark only the areas that apply to you. The outline of Figure 1 was presented four times, each corresponding to a different anatomical level as specified in the second question. The questionnaire was completed independently by the patients. In addition to the SFNPQ, the SFNSL was also administered.20 The difference between intermittent and continuous symptoms were published previously21 and were considered out of scope for this article. Data analysis The prevalence of granulomas, symptoms mentioned during consultations with the pulmonologist and neurologist, and pain as indicated in the SFNPQ were evaluated for the skin, muscles, and joints. The results were compared between healthy controls and sarcoidosis patients, with and without SFN, to examine the correspondence between actual granulomas in the respective organs, symptoms mentioned during consultations, and symptoms reported in the SFNPQ. Pain symptoms were examined based on three anatomical levels: skin, muscles, and joints. In addition to these three levels, the body was subdivided into seven areas: head, thorax, arms, hands, back/abdomen, legs and feet (see Figure 1). For each area, the prevalence of participants with symptoms and the correlation between the three levels were calculated. No distinction was made between intermittent and continuous symptoms. Additionally, odds ratio (OR) and chi-square were calculated to determine whether symptoms were more likely to be present in patients with sarcoidosis and probable SFN compared to those with sarcoidosis without SFN. Figure 1 Definitions of body areas displayed with a color map. 4 72 4
RkJQdWJsaXNoZXIy MjY0ODMw